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Abstract – Paxillin and p130CAS are two adaptor proteins localized at the focal adhesions which
play an important role in cell signaling, cell motility and oncogenic transformation. In this study we
evaluated the levels of paxillin and p130CAS in feline and canine mammary tumor tissues at
different stages of malignancy. The results obtained by Western blotting analysis showed no
significant differences in the amounts of paxillin and p130CAS between normal and non-invasive
tumor tissues. By contrast, mammary tumor tissues with the invasive phenotype showed lower
levels of paxillin P < 0.01 and higher levels of p130CAS P < 0.001 than normal tissues. The decrease
P < 0.001 of the amount of paxillin and the increase P < 0.001 of p130CAS levels were correlated
with the progression stage of malignancy. Since paxillin and p130CAS are involved in regulating cell
migration, our results suggest that low levels of paxillin together with high levels of p130CAS
expression may cause certain breast cancers to be more motile and possibly more aggressive. Thus,
both paxillin and p130CAS may represent useful prognosticators of feline and canine breast cancer
malignancy. 
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1. INTRODUCTION
The mammary gland is one of the most
common sites of tumor development in
dogs and cats [14]. Approximately 50% of
canine mammary tumors are malignant and
the most common malignant tumors are
solid carcinomas and adenocarcinomas.
Most tumors occur in dogs between 8 and
10 years of age. Mammary cancer occurs
much less frequently in cats than in dogs,
but when it does occur it is often malignant
and difficult to treat. Mammary cancer is
likely to strike 1 in 4000 cats. While this is
about half the rate as in dogs, when cats
develop mammary tumor it is often fatal.
Any adult female cat can develop mam-
mary cancer, but the median age is usually
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10–14 years. Eighty-five percent of mam-
mary tumors in cats are malignant adeno-
carcinomas. Other mammary tumors in
cats include duct papillomas, sarcomas and
adenomas. 
Whereas oncology research has been
much developed in humans and advanced
molecular diagnostic methodologies are
largely available in human medicine, the
methodologies employed in veterinary
oncology for diagnostic purposes are defi-
nitely inadequate. For diagnosis and prog-
nosis of mammary tumors in dogs and cats,
fine needle aspiration biopsies and histo-
logical diagnosis are used. However, there
is an extreme histological heterogeneity
among mammary gland tumors and it is
not uncommon for fine needle aspiration
biopsies to yield cells with characteristics
of inflammation as the dominant finding
rather than characteristics of malignancy.
Thus, there is a need to develop new
molecular diagnostic strategies for the
diagnosis and prognosis of mammary
tumors in dogs and cats. 
Invasion into surrounding tissues is a
prominent phenotype of cancer cells [18].
Regulatory mechanisms of cell motility is
critical in this process. The formation of
focal adhesions is a regulated process
involved in cellular movement. Focal
adhesions are structures which form at the
site of interaction between the cell actin
cytoskeleton and the extracellular matrix
(ECM). The focal adhesions contain multi-
ple proteins such as vinculin, talin and
tensin. Other proteins localised at focal
adhesions include kinases, phospholipases,
and proteases. Focal adhesion proteins are
key regulators of signal transduction
events [5]. The actin cytoskeleton needs to
be dynamic for cell shape change altera-
tions in cell contacts and cell motility. The
deregulation of cytoskeletal function
contributes to the transformation [27]. In
normal cells, the cytoskeleton is very sta-
ble and there is little movement of the
cells. In cells which have become cancer-
ous, the cytoskeleton is disrupted in such a
way as to increase cell motility.
Paxillin is a focal adhesion-associated
adaptor protein which plays a key role in
cell spreading and motility [23]. The pro-
tein was originally identified as a substrate
for the non-receptor tyrosine kinase onco-
gene pp60v-src in Rous sarcoma virus
transformed fibroblasts [6]. The human
paxillin cDNA was cloned using antibody
expression cloning in a K562 cDNA
library followed by the polymerase chain
reaction and hybridisation strategies [20].
The N-terminal domain of paxillin
contains five copies of a peptide sequence,
called the LD motif, which are known to
function as binding sites for other proteins.
The C-terminal half of paxillin is com-
prised of four LIM domains, which are
zinc-binding structures resembling a dou-
ble zinc finger domain. The focal adhesion
targeting sequence of paxillin is located in
the C-terminal half of the protein. Paxillin
is ubiquitously expressed, even though in
variable amounts, with low levels in plate-
lets and neuronal cells. It is highly
conserved among various species: the
homology between human and chicken
predicted amino acids is about 90% with
almost complete identity in the LIM
domains [22].
Paxillin interacts with several other
focal adhesion proteins such as talin,
tensin, and vinculin, as well as with impor-
tant signal transduction intermediates. The
tyrosine kinases p125FAK, RAFTK and
Csk, a negative regulator of p60src, are but
a few proteins which interact with paxillin
at focal adhesions [25].
p130CAS is another focal adhesion-
associated protein which has been sug-
gested to play an important role in cell
migration [2]. p130CAS was first identified
as a phosphotyrosine-containing protein in
cells transformed by the oncogenes v-src
and v-crk [12]. A cDNA clone encoding
p130CAS was isolated in 1994 [19] and its
predicted domain structure suggested that
it functions as an adapter or scaffolding
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protein. p130CAS contains an Src-homol-
ogy 3 (SH3) domain as well as multiple
phosphotyrosine motifs for binding of a
variety of SH2 domains [15, 19]. It is phos-
phorylated upon cell adhesion in a
p125FAK-p60src-dependent manner [17,
26]. p130CAS association with p125FAK
has been proposed to initiate a signal trans-
duction pathway to activate Erks [24].
Interestingly, activation of Erks has been
shown to regulate cell migration on ECM
by directly phosphorylating a cytoplasmic
target myosin light chain kinase [9]. How-
ever, pathways other than those involving
Erks may also be involved in the induction
of cell migration by p130CAS [2, 3, 10].
Even though both paxillin and p130CAS
have been shown to have a regulatory role
in focal adhesion dynamics and cell move-
ment [16], whether and how the two pro-
tein signaling pathways, which have been
studied in cultured cells, relate to signaling
in the complex organization of individual
tissues has not yet been established.
In this work we evaluated the expres-
sion levels of paxillin, p130CAS and other
focal adhesion-associated proteins (talin,
vinculin, α-actinin) in mammary tumor tis-
sues from cats and dogs. The expression
levels of the two proteins was correlated to
the progression stage of malignancy.
2. MATERIALS AND METHODS
2.1. Antibodies and chemicals
Rabbit polyclonal anti-paxillin IgG
(H-114) was purchased from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA,
USA); mouse monoclonal anti-paxillin
IgG (clones 349, 177, 165), and mono-
clonal anti-p130CAS IgG (clone 21) were
purchased from Transduction Laboratories
(Lexington, KY, USA); mouse mono-
clonal anti-vinculin IgG (clone VIN-11-5),
anti-talin IgG (clone 8D4), anti-α-actinin
IgM (clone BM-75.2) and horseradish per-
oxidase-conjugated goat anti-mouse and
anti-rabbit Ig, aprotinin, bovine serum
albumin (BSA), leupeptin, pepstatin from
Sigma (St. Louis, MO, USA).
2.2. Tissue sampling and processing
Mammary tumor tissues were obtained
from dogs and cats undergoing surgical
resection at the Department of Veterinary
Clinical Sciences of the University of
Napoli Federico II (Italy). The animals
were between 6 and 14 years old. Tumors
were classified by the criteria of the World
Health Organization [7] and were graded
as being well, moderately or poorly differ-
entiated (grades 1 to 3, respectively) on the
basis of the following parameters: degree
of tubule formation, hyperchromatism and
number of mitoses, and irregularity of size,
shape and staining of the nuclei. The sam-
ples consisted of five canine and five feline
mammary adenomas, five canine condro-
mas of the mammary gland, five canine
mammary adenocarcinomas at grade 1,
five canine mammary adenocarcinomas at
grade 2, five canine mammary adenocarci-
nomas at grade 3 and five feline solid car-
cinomas of the breast. Adjacent normal
mammary specimens were obtained from
the sites ~5–10 cm apart from the primary
tumors. Tissue samples were divided into
two parts: one part was fixed in formalin
for histological routine diagnosis; another
part of the fresh material was perfused
thoroughly with cold 0.9% NaCl and
homogenized by an Ultraturrax L-407 at
4 °C with 5 mL/1.5 g tissue of buffer
containing 10 mM Tris-HCl pH 7.4,
10 mM EDTA, 5 mM dithiotreitol, 10%
glycerol, 0.1 U trypsin per mL aprotinin,
10 µg/mL leupeptin and 4 µM pepstatin.
Homogenates were divided into small aliq-
uots and stored at –80 °C until use.
The amount of total proteins in each
sample was determined by the Bio-Rad DC
protein assay (Bio-Rad Laboratories,
Hercules, CA, USA).
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2.3. Electrophoresis and Western blots
Samples containing equal amounts of
proteins were boiled for 5 min in SDS sam-
ple buffer (50 mM Tris-HCl, pH 6.8, 2%
SDS, 10% glycerol, 0.1% bromophenol
blue and 5% β-mercaptoethanol) and run
on 7.5% SDS/polyacrylamide gels. Fol-
lowing electrophoresis, the samples were
transferred to nitrocellulose using a Mini
Trans-Blot apparatus (Bio-Rad) according
to the manufacturer’s instructions, blocked
for 1 h at 42 °C in Tris/NaCl/Pi containing
5% BSA, and washed with Tris/NaCl/Pi/
Tween (150 mM NaCl, 20 mM Tris-HCl,
pH 7.4, 0.1% Tween-20). The blots were
incubated for 2 h with anti-paxillin Ig
(1:10000) or anti-p130CAS (1:1000) or
anti-vinculin (1:500) or anti α-actinin
(1:500). After incubation the filters were
washed three times with Tris/NaCl/Pi/
Tween and incubated for 2 h with peroxi-
dase conjugated anti-(mouse IgG) Ig
diluted 1:3000 in Tris/NaCl/Pi, 1% BSA
and washed three times with Tris/NaCl/Pi/
Tween. The proteins were visualized by an
ECL chemiluminescence kit (Amersham
Corp., Little Chalfont, UK). The blots were
stripped and reprobed against anti-talin
antibody (1:500) to confirm equal loading
of proteins in each lane. Protein expression
levels were quantitatively estimated by
densitometry using a Discover Pharmacia
scanner equipped with a sun spark classic
densitometric workstation. The focal adhe-
sion-associated protein concentrations
were normalized to the talin level and
expressed as the densitometric ratio.
2.4. Statistical analysis
The paired Student t test was used for
statistical analysis and P < 0.05 was consid-
ered to indicate a significant difference.
3. RESULTS 
Mammary tissue samples obtained from
cats were homogenized, loaded onto a
SDS-polyacrylamide gel and immunoblot-
ted with paxillin, p130CAS, talin, vinculin
and α-actinin antibodies. No difference in
the amount of paxillin and p130CAS was
detected in normal and tumor tissues from
cats affected by breast adenoma (Fig. 1,
panels A and B, upper blots, lanes 1 and 2).
Conversely, a concomitant decrease of the
amount of paxillin and increase of
p130CAS as compared to normal tissues of
the same animal was observed in tumor tis-
sues from cats affected by breast solid car-
cinoma (Fig. 1, panels A and B, upper
blots, lanes 3 and 4). The blots in A and B
were stripped and reprobed with an anti-
talin antibody to be sure of equal loading in
all lanes (Fig. 1, panels A and B, lower
blots). No difference in the amount of the
other focal adhesion-associated proteins
vinculin and α-actinin was detected in
tumor tissues as compared to normal tis-
sues from the same animal (Fig. 1,
panel C). Similar results were obtained
from five samples of feline breast solid car-
cinomas derived from different animals.
The degrees of paxillin reduction, as
compared to normal mammary tissues
derived from the same animal, were
slightly varied among tumor tissues from
different animals. Statistical analysis of
paxillin/talin densitometric ratios showed
that average paxillin expression levels
were significantly lower (P < 0.01) in sam-
ples of feline breast solid carcinoma than
in adjacent normal mammary tissues
(Fig. 2, panel A).
The degrees of p130CAS increase, as
compared to normal mammary tissues
derived from the same animal, were
slightly varied among tumor tissues from
different animals. Statistical analysis of
p130CAS/talin densitometric ratios showed
that average p130CAS expression levels
were significantly higher (P < 0.001) in
samples of feline breast solid carcinoma
than in adjacent normal mammary tissues
(Fig. 2, panel B).
Mammary tissue samples obtained from
dogs were homogenized, loaded onto a
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SDS-polyacrylamide gel and immunoblot-
ted with paxillin, p130CAS, talin, vinculin
and α-actinin antibodies. No difference in
the amount of paxillin and p130CAS as well
as of the other cytoskeletal proteins vincu-
lin and α-actinin were observed between
normal and tumor tissues from dogs
affected by breast adenoma or breast
condroma (Fig. 3, panels A and B upper
blots, panel C). The blots in A and B were
Figure 1. Homogenized samples from feline
breast adenoma (lane 2), feline breast solid
carcinoma (lane 4) and normal mammary tissues
of the same animal (lanes 1 and 3) were
electrophorized on 7.5% SDS-PAGE and
analysed by Western blot with monoclonal mouse
anti-paxillin IgG (panel A, upper blot),
monoclonal mouse anti-p130CAS IgG (panel B,
upper blot), monoclonal mouse anti-α-actinin
and monoclonal mouse anti-vinculin (panel C).
The blots in panels A and B were stripped and
reprobed against anti-talin antibody (lower blots).
Molecular mass markers are indicated on the left. 
Figure 2. A comparison of average paxillin
(panel A) and p130CAS (panel B) expression
levels in feline breast solid carcinoma (T) and
adjacent normal mammary tissues (N). Data
represent the mean ± S.D.
SDS-polyacrylamide gel and immunoblot-
ted with paxillin, p130CAS, talin, vinculin
and α-actinin antibodies. No difference in
the amount of paxillin and p130CAS as well
as of the other cytoskeletal proteins vincu-
lin and α-actinin were observed between
normal and tumor tissues from dogs
affected by breast adenoma or breast
condroma (Fig. 3, panels A and B upper
blots, panel C). The blots in A and B were
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stripped and reprobed with an anti-talin
antibody to be sure of equal loading in all
lanes (Fig. 3, panels A and B, lower blots).
Similar results were obtained in at least
five experiments of identical design per-
formed by using mammary tissues from
different animals.
Next, the expression levels of focal
adhesion-associated proteins in sample tis-
sues from dogs affected by adenocarci-
noma of grade 1, grade 2 and grade 3 were
analysed. A decrease of the amount of pax-
illin and an increase of p130CAS levels
were detected in tumor tissues as compared
to normal tissues (Fig. 4, panels A and B,
upper blots). The decrease of paxillin
expression levels and the concomitant
increase of p130CAS expression levels cor-
related with the tumor grading. The blots in
A and B were stripped and reprobed with
an anti-talin antibody to be sure of equal
loading in all lanes (Fig. 4, panels A and B,
lower blots). Vinculin and α-actinin levels
were the same in tumor tissues and respec-
tive normal tissues (Fig. 4, panel C). Simi-
lar results were obtained from five samples
of each type of tumor derived from differ-
ent animals. 
The degrees of paxillin reduction, as
compared to normal mammary tissues
derived from the same animal, were
slightly varied among tumor tissues from
different animals. An almost complete dis-
appearance of paxillin was always
observed in all five samples of canine
mammary tumors of grade 3. Statistical
analysis of paxillin/talin densitometric
ratios showed that average paxillin expres-
sion levels were significantly lower
(P < 0.001) in samples of canine breast
adenocarcinoma than in adjacent normal
mammary tissues and the decrease of the
amount of paxillin was significantly corre-
lated with the progression stage of malig-
nancy (Fig. 5, panel A ).
The degrees of p130CAS increase, as
compared to normal mammary tissues
derived from the same animal, were
slightly varied among tumor tissues from
Figure 3. Homogenized samples from canine
breast adenoma (lane 2), canine breast
condroma (lane 4) and normal mammary
tissues of the same animal (lanes 1 and 3) were
electrophorized on 7.5% SDS-PAGE and
analyzed by Western blot with monoclonal
mouse anti-paxillin IgG (panel A, upper blot),
monoclonal mouse anti-p130CAS IgG (panel B,
upper blot), monoclonal mouse anti-α-actinin
and monoclonal mouse anti-vinculin (panel C).
The blots in panels A and B were stripped and
reprobed against anti-talin antibody (lower
blots). Molecular mass markers are indicated
on the left.
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different animals. Statistical analysis of
p130CAS/talin densitometric ratios showed
that average p130CAS expression levels
were significantly higher (P < 0.001) in
samples of canine breast adenocarcinoma
than in adjacent normal mammary tissues
and the increase of p130CAS levels was
significantly correlated with the progres-
sion stage of malignancy (Fig. 5, panel B).
Experiments performed by using differ-
ent clones of monoclonal or polyclonal
Figure 4. Homogenized samples from canine
breast adenocarcinoma at grade 1 (lane 2), canine
breast adenocarcinoma at grade 2 (lane 4),
canine breast adenocarcinoma at grade 3 (lane 6)
and normal mammary tissues of the same animal
(lanes 1, 3, 5) were electrophorized on 7.5%
SDS-PAGE and analyzed by Western blot with
monoclonal mouse anti-paxillin IgG (panel A,
upper blot), monoclonal mouse anti-p130CAS
IgG (panel B, upper blot), monoclonal mouse
anti-α-actinin and monoclonal mouse anti-
vinculin (panel C). The blots in panels A and B
were stripped and reprobed against anti-talin
antibody (lower blots). Molecular mass markers
are indicated on the left. 
Figure 5. A comparison of average paxillin
(panel A) and p130CAS (panel B) expression
levels in canine breast adenocarcinomas at
grade 1 (T1), grade 2 (T2), grade 3 (T3), and
canine adjacent normal mammary tissues (N).
Data represent the mean ± S.D.
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anti-paxillin antibodies yielded similar
results, thus indicating that a possible
tumor-specific modification of paxillin at
or near sites of the epitope recognition is
unlikely to be responsible for the reduced
detection in both canine and feline breast
cancers. 
4. DISCUSSION
In this study we measured the expres-
sion levels of five focal adhesion-associ-
ated proteins (paxillin, p130CAS, talin, vin-
culin, α-actinin) in different types of feline
and canine mammary tumor tissues. No
significant differences in the protein
expression levels between normal and non-
invasive tumor tissues were observed. By
contrast, mammary tumor tissues with an
invasive phenotype showed lower levels of
paxillin and higher levels of p130CAS than
normal tissues. The decrease of the amount
of paxillin and the increase of p130CAS
levels correlated with the progression stage
of malignancy.
Further studies are required to establish
whether the observed down-regulation of
paxillin in tumor tissues is due to a proteo-
lytic degradation of the protein or to a
down-regulation of paxillin mRNA
expression. Northern blot analysis was not
performed due to the limited availability of
the tissues. Moreover, the observed
decrease of the paxillin amount in tumor
tissues as compared to normal tissues
refers to the total amount of cellular paxil-
lin; it would be interesting to investigate
whether a more pronounced decrease of
the amount of paxillin localized at focal
adhesions would occur rather than a
decrease of the cytosolic localized protein
levels. Finally, whether the observed up-
regulation of p130CAS expression in tumor
tissues could be due to increased synthesis
of newly transcribed mRNA and/or to the
enhanced stability of p130CAS mRNA
should be evaluated.
The amount of paxillin has been shown
to be significantly reduced during mitosis
of the cell cycle, whereas the expression
levels of other focal adhesion proteins such
as talin, vinculin and p125FAK remained
unchanged [28]. Low levels or the absence
of only paxillin expression have also been
demonstrated in certain human lung can-
cers [21] and liver metastasis [1]. Cell
motility, as assessed by migration mem-
brane ruffling and the formation of lamel-
lipodia and filopodia, has been shown to be
inhibited by paxillin overexpression in
lung cancer cell lines [21]. Many studies
using different approaches to address the
role of paxillin in the cell have produced
the same conclusion that paxillin controls
cell spreading and motility [23]. Overex-
pression of wild type paxillin inhibits the
ability of lysophosphatidic acid stimulated
MM-1 rat hepatoma tumor cells to invade
a monolayer of primary mesothelial cells
[29]. Paxillin has also been implicated in
the control of cell spreading and motility
by the α4 integrin subunit [11], since anα4 mutant defective for paxillin binding
failed to block cell spreading. 
p130CAS appears to function as an
important “molecular switch” for the
induction of migration signals via its bind-
ing to the SH2/SH3-adapter protein Crk
[10]. p130CAS overexpression enhances
cell migration of COS and FG-M pancre-
atic carcinoma cells plated on vitronectin.
Expression of a substrate binding domain
deletion of p130CAS that is deficient for
Crk binding inhibits this effect [10].
p130CAS-Crk signaling also appears to be
important for haptotaxis involving ECM
components other than vitronectin. For
example, cells expressing a mutant of the
α7 integrin subunit exhibit diminished
p130CAS phosphorylation and p130CAS-
Crk association resulting in a decreased
migration on laminin [13]. p130CAS-defi-
cient fibroblasts show decreased hapto-
taxis toward fibronectin, a decreased abil-
ity to migrate into the gap in a wound
healing assay, and a decreased basal
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and serum-induced invasion through a
3-dimensional collagen matrix [4, 8].
Finally, the close functional relation-
ship between p125FAK and p130CAS also
contributes to the role of p130CAS in cell
migration. Overexpression of p125FAK in
CHO cells enhances fibronectin-mediated
haptotaxis and this effect can be inhibited
by co-expression of the p130CAS SH3
domain [3]. Under these conditions the
p130CAS SH3 domain competes with
endogenous p130CAS in binding to
p125FAK, thus inhibiting functional inter-
actions between p125FAK and full-length
p130CAS.
Metastasising cells tend not to form
clusters and exhibit cell-to-cell contacts,
which are the opposite of normally func-
tioning cells. Low levels of paxillin and
high levels of p130CAS may confer to can-
cer cells an advantage in migration by
interfering with the attachment with the
extracellular matrix, and this may involve
blocking or sequestering signaling mole-
cules or interfering with signal transduc-
tion from focal adhesions. Thus, the obser-
vation that paxillin levels are reduced
and concomitantly p130CAS levels are
increased in malignant mammary tumors
at high grades of progression and are there-
fore more aggressive, may lead to further
insights into the role of paxillin and
p130CAS in normal and transformed cells.
The important finding emerging from
this study is the presence of low levels of
paxillin and high levels of p130CAS in
invasive feline and canine mammary
tumors. Even though additional studies
using a larger number of clinical samples
are needed to validate these preliminary
findings, to the best of our knowledge this
is the first report demonstrating a signifi-
cant correlation between the expression
levels of paxillin and p130CAS and the
mammary tumor malignancy stage. Thus,
paxillin and p130CAS may represent useful
prognosticators of feline and canine breast
cancer malignancy. Whether the two focal
adhesion proteins could be used as prog-
nosticators of human breast cancer malig-
nancy would be intriguing to establish. 
Our results may provide the basis for
developing new diagnostic and therapeutic
strategies in veterinary oncology. At the
moment we are investigating whether pax-
illin and p130CAS expression is down- or
up-regulated in domestic animal cancers
other than mammary tumors.
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